Lundbeck (HLUN-B.CO) Financial Analysis & Valuation | Quarter Chart
Lundbeck (HLUN-B.CO)
HLUN-B.COPrice: $6.54
Fair Value: 🔒
🔒score
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena for sc... more
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and ... more
Description
Shares
| Market Cap | $5.19B | Exchange | CPH |
| Sector | Healthcare | Industry | Drug Manufacturers - Specialty & Generic |
| Country | DK | CEO | Charl van Zyl |
| IPO Date | 2022-06-10 | CAGR | 0.04% |
| Employees | 5,315 | Website | www.lundbeck.com |
| Div. Yield | 2.69% | Payout Ratio | 0.31% |
| Buy Back Yield | 0.06% | Total Yield | 2.75% |
HLUN-B.CO chart loading...
Fundamentals
Technicals
| Enterprise Value | $46.69B | P/E Ratio | 11.25 |
| Forward P/E | 6.88 | PEG Ratio | 0.24 |
| P/S Ratio | 0.02 | P/B Ratio | 0.02 |
| P/CF Ratio | 0.02 | P/FCF Ratio | 0.02 |
| EPS | $0.58 | EPS Growth 1Y | 34.48% |
| EPS Growth 3Y | 172.56% | EPS Growth 5Y | -56.29% |
| Revenue Growth 1Y | 13.64% | Gross Margin | 0.82% |
| Operating Margin | 0.18% | Profit Margin | 0.15% |
| ROE | 0.14% | ROA | 0.07% |
| ROCE | 0.1% | Current Ratio | 1.59 |
| Quick Ratio | 1.08 | Cash Ratio | 0.35 |
| Debt/Equity | 0.56 | Interest Coverage | 6.73 |
| Altman Z Score | 2.2 | Piotroski Score | 4 |